Effects of TCN2 776C>G on vitamin B12, folate, and total homocysteine levels in kidney transplant patients

Kidney International

Volumn 65, Issue 5, 2004, Pages 1877-1881

  Winkelmayer, Wolfgang C ^b   Skoupy, Sonja ^b   Eberle, Corinna ^b   Födinger, Manuela ^b   Sunder Plassmann, Gere ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

Folate; Genetic polymorphism; Homocysteine; Kidney transplants; Mutation; TCN2; Vitamin B12

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE;

ADULT; AGED; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; DNA POLYMORPHISM; FEMALE; FOLIC ACID BLOOD LEVEL; GENE; GENE FREQUENCY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; KIDNEY ALLOGRAFT; LINEAR REGRESSION ANALYSIS; MALE; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; TCN2 776 G GENE; VITAMIN BLOOD LEVEL;

EID: 2342524607     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00592.x     Document Type: Conference Paper

References (30)

1. HANKEY GJ, EIKELBOOM JW: Homocysteine and vascular disease. Lancet 354:407-413, 1999
2. THE HOMOCYSTEINE STUDIES COLLABORATION: Homocysteine and risk of ischemic heart disease and stroke. A meta-analysis. JAMA 288:2015-2022, 2002
3. BOSTOM AG, CULLETON BF: Hyperhomocysteinemia in chronic renal disease. J Am Soc Nephrol 10:891-900, 1999
4. FÖDINGER M, HÖRL WH, SUNDER-PLASSMANN G: Molecular biology of 5,10-methylenetetrahydrofolate reductase. J Nephrol 13:20-33, 2000
5. WINKELMAYER WC, EBERLE C, FÖDINGER M, SUNDER-PLASSMANN G: Effects of the glutamate carboxypeptidase II (GCP2 1561C>T) and reduced folate carrier (AFC1 80G>A) allelic variants on folate and total homocysteine levels in kidney transplant patients. Kidney Int 63: 2280-2285, 2003
6. FÖDINGER M, DIERKES J, SKOUPY S, et al: Effect of glutamate carboxypeptidase II and reduced folate carrier polymorphisms on folate and total homocysteine concentrations in dialysis patients. J Am Soc Nephrol 14:1314-1319, 2003
7. 12 concentrations in renal transplant patients. Atherosclerosis 2004, in press
8. 12 cellular availability in end-stage renal disease patients. Kidney Int 64:1095-1100, 2003
9. NAMOUR F, OLIVIER JL, ABDELMOUTTALEB I, et al: Transcobalamin codon 259 polymorphism in HT-29 and Caco-2 cells and in Caucasians: Relation to transcobalamin and homocysteine concentration in blood. Blood 97:1092-1098, 2001
10. MCCADDON A, BLENNOW K, HUDSON P, et al: Transcobalamin polymorphism and homocysteine. Blood 98:3497-3499, 2001
11. 12 status in healthy older adults. Blood 100:718-720, 2002
12. AFMAN LA, LIEVERS KJ, VAN DER PUT NM, et al: Single nucleotide polymorphisms in the transcobalamin gene: Relationship with transcobalamin concentrations and risk for neural tube defects. Eur J Hum Genet 10:433-438, 2002
13. LIEVERS KJ, AFMAN LA, KLUIJTMANS LA, et al: Polymorphisms in the transcobalamin gene: Association with plasma homocysteine in healthy individuals and vascular disease patients. Clin Chem 48:1383-1389, 2002
14. SUNDER-PLASSMANN G, FÖDINGER M: Genetic determinants of the homocysteine level. Kidney Int 63 (Suppl 84):S141-S144, 2003
15. 12 plasma concentrations in kidney graft recipients. J Am Soc Nephrol 11:1918-1925, 2000
16. AMERICAN SOCIETY OF HUMAN GENETICS/AMERICAN COLLEGE OF MEDICAL GENETICS TEST AND TECHNOLOGY TRANSFER COMMITTEE WORKING GROUP. ASHG/ACMG Statement. Measurement and use of total plasma homocysteine. Am J Hum Genet 63:1541-1543, 1998
17. COCKCROFT DW, GAULT MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
18. FROSST P, BLOM HJ, MILOS R, et al: A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase [letter]. Nat Genet 10:111-113, 1995
19. WEISBERG I, TRAN P, CHRISTENSEN B, et al: A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64:169-172, 1998
20. THOMPSON SG, BARBER JA: How should cost data in pragmatic randomised trials be analysed? Br Med J 320:1197-1200, 2000
21. DIEHR P, YANEZ D, ASH A, et al: Methods for analyzing health care utilization and costs. Annu Rev Public Health 20:125-144, 1999
22. NATIONAL KIDNEY FOUNDATION: K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, classification, and stratification. Part 4. Definition and classification of stages of chronic kidney disease. Am J Kidney Dis 39(Suppl 1):S46-75, 2002
23. ZETTERBERG H, COPPOLA A, D'ANGELO A, et al: No association between the MTHFR A1298C and transcobalamin C776G genetic polymorphisms and hyperhomocysteinemia in thrombotic disease. Thromb Res 108:127-131, 2002
24. ZETTERBERG H, NEXO E, REGLAND B, et al: The transcobalamin (TC) codon 259 genetic polymorphism influences holo-TC concentration in cerebrospinal fluid from patients with Alzheimer disease. Clin Chem 49:1195-1198, 2003
25. NAMOUR F, GUÉANT JL: Transcobalamin polymorphism, homocysteine, and aging [letter]. Blood 98:3499, 2001
26. IOANNIDIS JP, TRIKALINOS TA, NTZANI EE, CONTOPOULOS-IOANNIDIS DG: Genetic associations in large versus small studies: An empirical assessment. Lancet 361:567-571, 2003
27. COLHOUN HM, MCKEIGUE PM, DAVEY SMITH G: Problems of reporting genetic associations with complex outcomes. Lancet 361:865-872, 2003
28. SMULDERS YM, DE MAN AME, STEHOUWER CDA, SLAATS EH: Trimethoprim and fasting plasma homocysteine [letter]. Lancet 352:1828-1829, 1998
29. BOSTOM AG, GOHH RY, BEAULIEU AJ, et al: Determinants of fasting plasma total homocysteine levels among chronic stable renal transplant recipients. Transplantation 86:257-261, 1999
30. FRIEDMAN AN, ROSENBERG IH, SELHUB J, et al: Hyperhomocysteinemia in renal transplant recipients. Am J Transplant 2:308-313, 2002